# To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females

> **NCT01478503** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 96 (actual)

## Conditions studied

- Pharmacokinetics
- Healthy Subjects

## Interventions

- **DRUG:** mirabegron OCAS
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01478503
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2013-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01478503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01478503, "To Evaluate the Blood and Urine Concentration and the Safety and Tolerability of Increasing Repeated Doses of Mirabegron (YM178) OCAS in Healthy Young and Elderly Males and Healthy Young and Elderly Females". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01478503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*